Seroepidemiology of hepatitis E in patients on haemodialysis in Croatia

International Urology and Nephrology - Data on the seroprevalence of hepatitis E virus (HEV) in heamodialysis (HD) patients are conflicting, ranging from 0 to 44%. The aim of this study was to...     

Minimally invasive approach (robotic and laparoscopic) to biliary-enteric fistula secondary to cholecystectomy bile duct injury

Spontaneous biliary-enteric fistula after laparoscopic cholecystectomy bile duct injury is an extremely rare entity. Y-en-Roux hepaticojejunostomy has been demonstrated to be an effective surgical technique to repair iatrogenic bile duct injuries. Seven consecutive patients underwent robotic-assisted (n = 5) and laparoscopic (n = 2) biliary-enteric fistula resection and bile duct repair at our hospital from January 2012 to May 2017. We reported our technique and described post-procedural outcomes. The mean age was 52.4 years, mostly females (n = 5). The mean operative time was 240 min for laparoscopic cases and 322 min for robotic surgery, and the mean estimated blood loss was 300 mL for laparoscopic and 204 mL for robotic cases. In both groups, oral feeding was resumed between day 2 or 3 and hospital length of stay was 4–8 days. Immediate postoperative outcomes were uneventful in all patients. With a median of 9 months of follow-up (3–52 months), no patients developed anastomosis-related complications. We observed in this series an adequate identification and dissection of the fistulous biliary-enteric tract, a safe closure of the fistulous orifice in the gastrointestinal tract and a successful bile duct repair, providing the benefits of minimally invasive surgery.     

Management of early ankle osteoarthritis through anterior joint-preserving surgery: a retrospective evaluation at mid- to long-term follow-up

European Journal of Orthopaedic Surgery & Traumatology - Chronic anterior ankle pain is a recognized and straightforward characteristic of anterior impingement syndrome. This retrospective...     

Adoption of Expansion Margins to Reduce the Dose Received by the Coronary Arteries and the Risk of Cardiovascular Events in Lymphoma Patients

PurposeMediastinal radiation therapy (RT) in patients with lymphoma implies involuntary coronary artery (CA) exposure, resulting in an increased risk of coronary artery disease (CAD). Accurate delineation of CAs may spare them from higher RT doses. However, heart motion affects the estimation of the dose received by CAs. An expansion margin (planning organ at risk volume [PRV]), encompassing the nearby area where CAs displace, may compensate for these uncertainties, reducing CA dose and CAD risk. Our study aimed to evaluate if a planning process optimized on CA-specific PRVs, rather than just on CAs, could provide any dosimetric or clinical benefit.Methods and MaterialsForty patients receiving RT for mediastinal lymphomas were included. We contoured left main trunk, left anterior descending, left circumflex, and right coronary arteries. An isotropic PRV was then applied to all CAs, in accordance with literature data. A comparison was then performed by optimizing treatment plans either on CAs or on PRVs, to detect any difference in CA sparing in terms of maximum (D_max), median (D_med), and mean (D_mean) dose. We then investigated, through risk modeling, if any dosimetric benefit obtained with the PRV-related optimization process could translate to a lower risk of ischemic complications.ResultsPlan optimization on PRVs demonstrated a significant dose reduction (range, 7%-9%) in D_max, D_med, and D_mean for the whole coronary tree, and even higher dose reductions when vessels were located 5- to 20-mm from PTV (range, 13%-15%), especially for left main trunk and left circumflex (range, 16%-21%). This translated to a mean risk reduction of developing CAD of 12% (P < .01), which increased to 17% when CAs were located 5- to 20-mm from PTV.ConclusionsIntegration of CA-related PRVs in the optimization process reduces the dose received by CAs and translates to a meaningful prevention of CAD risk in patients with lymphoma treated with mediastinal RT.     

Management of patients with acute myeloid leukemia undergoing therapy with midostaurin: a focus on antifungal prophylaxis

Both therapy and prophylaxis for infectious complications during the treatment of acute myeloid leukemia (AML) have improved, although invasive fungal disease still remains a life‐threatening occurrence. Accordingly, prophylactic strategies with effective and well‐tolerated antifungals remain a cornerstone of management. Herein, the recent literature on antifungal prophylaxis used during the treatment of AML is reviewed, with a focus on the use in combination with midostaurin. The multikinase inhibitor midostaurin targets FMS‐like tyrosine kinase 3 (FLT3) and is approved, in association with 7 + 3, for the treatment of adult patients with newly diagnosed FLT3‐mutated AML. Midostaurin has been shown to extend both overall and event‐free survival in AML patients with an FLT3 mutation and is now the standard of care in FLT3+ AML. Antifungal prophylaxis should be adopted during all phases of treatment in all AML patients, and the strong CYP3A4 inhibitor posaconazole is frequently the preferred agent. As midostaurin is metabolized primarily by CYP3A4, there is a potential for drug–drug interactions that requires further evaluation. At present, the available data suggest that there are no absolute contraindications for coadministration of midostaurin with posaconazole, albeit with cautious monitoring. Considering the survival advantage offered by midostarin, concomitant administration of strong CYP3A4 inhibitors should not be ruled out, although such use should be evaluated cautiously and used on a case‐by‐case basis only if there are no suitable alternatives. It should also be kept in mind that patients with invasive fungal infection undergoing therapy for AML with midostaurin may need prolonged antifungal therapy, which must be based on the administration of the appropriate antifungal agent.     

Actual insights into the clinical management of febrile seizures

Febrile seizures (FS) are a benign epileptic manifestation of infancy occurring between 3 months and 5 years of age and affecting an estimated 2–5 % of children. They have usually no important negative effects on motor and cognitive development. Simple FS (generalized seizures, lasting less than 10 min and single episodes during the same febrile event) have a benign prognosis in almost all cases and do not require an extensive diagnostic workup. In complex FS (focal semiology and lasting more than 10 min, more than one episode during the same febrile event), a more detailed clinical, electroencephalographic, laboratory, and neuroimaging evaluation is necessary because of a higher percentage of underlying detectable causes and a mildly higher risk for later development of epilepsy. Febrile status epilepticus is the most severe type of complex FS even if its morbidity and mortality is extremely low. Simple FS plus (more than one convulsive episode in 24 h) have the same benign prognosis of simple FS. Neither intermittent nor continuous prophylaxis is actually recommended both in simple and complex FS because its side effects outweigh its possible benefits. Conclusion: This review summarizes recent developments into the clinical management of FS including a suggested algorithm for simple and complex FS, the concept of simple FS plus, the controversies about the relationships between FS and hippocampal sclerosis, the relationships between FS and complex syndrome such as Dravet syndrome, genetic epilepsy with FS plus or febrile infection-related epilepsy syndrome, and the results of recent epidemiologic studies on febrile status epilepticus.